CARDENE SR
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Feb 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
CARDENE SR by Chiesi is mechanism of action nicardipine is a calcium entry blocker (slow channel blocker or calcium ion antagonist) that inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. Approved for hypertension. First approved in 1992.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDENE SR (nicardipine) is an extended-release oral calcium channel blocker approved in 1992 for hypertension management. It selectively inhibits calcium influx into vascular smooth muscle with minimal cardiac effects, providing sustained blood pressure control.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100) suggests contracting team and focus shifting to generic transition or next-generation asset pipelines.
Mechanism of Action
Mechanism of Action Nicardipine is a calcium entry blocker (slow channel blocker or calcium ion antagonist) that inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. The contractile processes of cardiac muscle and…
Indications (1)
Career Relevance
Career opportunities on CARDENE SR are highly constrained given LOE-approaching status and zero linked job count. Roles available focus on defending market share against generics and managed care negotiations rather than growth or innovation.
Worked on CARDENE SR at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.